A near miss for prostate cancer immunotherapy
Mené sur 799 patients atteints d'un cancer métastatique de la prostate résistant à la castration et ayant progressé après une chimiothérapie par docétaxel, cet essai multicentrique de phase III évalue l'intérêt, du point de vue de la survie globale, et la toxicité d'un ajout d'ipilimumab à une radiothérapie
Immunotherapy has not yet had a major effect on the treatment of prostate cancer. Sipuleucel-T, a vaccine that targets prostatic acid phosphatase and involves the administration of activated autologous dendritic cells, has been approved for the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. However, its use has been limited by cost, logistics, and concerns about the design of the IMPACT trial, 1 which was pivotal to its approval. Along ...
The Lancet Oncology , commentaire, 2013